Previous 10 | Next 10 |
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria PR Newswire INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's...
2024-06-25 06:30:00 ET Summary Six years ago, Apple became a $1 trillion company, not long before oil titan Saudi Aramco publicly debuted with a 13-digit market capitalization. Chipmaker Broadcom is riding an artificial intelligence wave. Eli Lilly is also on its way, thanks to th...
2024-06-24 15:56:56 ET Here's why Fundstrat's Tom Lee says the S&P 500 may reach 15,000 by 2030 ' Inflation is not the only risk we face', says Fed's Mary Daly The Fed could be running the risk of delaying cuts too long - Pantheon Macroeconomics S&P 500 E...
2024-06-24 15:17:13 ET More on Inspire Medical, ResMed Inspire Medical Systems: A Post Q1 Assessment ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug Inspire Medical Systems, Inc. (INSP) Q1 2024 Earnings Call Transcript ...
2024-06-24 14:51:58 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Lilly, Novo Nordisk to d...
2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...
Eli Lilly and Company (NYSE: LLY) is one of today's top gainers. The company's shares have moved 1.95% on the day to $901.08. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Hu...
Lilly Declares Third-Quarter 2024 Dividend PR Newswire INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stoc...
2024-06-24 11:14:09 ET This week marks the last handful of trading days for H1 2024, as market participants watched so far this year the benchmark S&P 500 ( SP500 ) advance 15.1% year to date.... Read the full article on Seeking Alpha For further details see: Top...
2024-06-24 09:21:19 ET More on Altimmune Altimmune: Going All-In On Pemvidutide Altimmune: A Potential Minor Player In The Massive GLP-1 Space Altimmune's Pemvidutide Is Not To Be Dismissed Altimmune Q1 2024 Earnings Preview Altimmune falls after Q4 r...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
2024-07-02 16:00:05 ET Terence Flynn from Morgan Stanley issued a price target of $1,023.00 for LLY on 2024-07-02 14:30:00. The adjusted price target was set to $1,023.00. At the time of the announcement, LLY was trading at $906.1521. The overall price target consensus i...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participan...